Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
ST-Elevation Myocardial Infarction 33 Days after Lung Transplant in a Patient with Non-Significant CAD before Transplantation: A Case Report.

Journal of clinical and diagnostic research : JCDR

Parsa SA, Khaheshi I, Dousti A, Naghashzadeh F, Ataeinia B.
PMID: 27437285
J Clin Diagn Res. 2016 May;10(5):OD23-4. doi: 10.7860/JCDR/2016/18830.7800. Epub 2016 May 01.

Acute myocardial infarction after lung transplantation is not well illustrated in the literature. We present a patient with documented non significant Coronary Artery Disease (CAD) in coronary angiography before lung transplant who was referred to our hospital with acute...

Cite
Parsa SA, Khaheshi I, Dousti A, et al. ST-Elevation Myocardial Infarction 33 Days after Lung Transplant in a Patient with Non-Significant CAD before Transplantation: A Case Report. J Clin Diagn Res. 2016;10(5):OD23-4doi: 10.7860/JCDR/2016/18830.7800.
Parsa, S. A., Khaheshi, I., Dousti, A., Naghashzadeh, F., & Ataeinia, B. (2016). ST-Elevation Myocardial Infarction 33 Days after Lung Transplant in a Patient with Non-Significant CAD before Transplantation: A Case Report. Journal of clinical and diagnostic research : JCDR, 10(5), OD23-4. https://doi.org/10.7860/JCDR/2016/18830.7800
Parsa, Saeed Alipour, et al. "ST-Elevation Myocardial Infarction 33 Days after Lung Transplant in a Patient with Non-Significant CAD before Transplantation: A Case Report." Journal of clinical and diagnostic research : JCDR vol. 10,5 (2016): OD23-4. doi: https://doi.org/10.7860/JCDR/2016/18830.7800
Parsa SA, Khaheshi I, Dousti A, Naghashzadeh F, Ataeinia B. ST-Elevation Myocardial Infarction 33 Days after Lung Transplant in a Patient with Non-Significant CAD before Transplantation: A Case Report. J Clin Diagn Res. 2016 May;10(5):OD23-4. doi: 10.7860/JCDR/2016/18830.7800. Epub 2016 May 01. PMID: 27437285; PMCID: PMC4948461.
Copy Download .nbib Format: NLM
Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor.

EXCLI journal

Ataeinia B, Loberg C, Kravets H, Beheshti M, von Mallek D, Mottaghy FM, Heinzel A.
PMID: 31338000
EXCLI J. 2019 May 21;18:273-276. doi: 10.17179/excli2019-1220. eCollection 2019.

We present the case of a 77 year old male patient with metastatic pancreatic neuroendocrine tumor (NET). The patient was initially treated by extensive surgical resection that however, led to severe complications with delayed recovery. During follow-up, a number...

Cite
Ataeinia B, Loberg C, Kravets H, et al. Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor. EXCLI J. 2019;18:273-276doi: 10.17179/excli2019-1220.
Ataeinia, B., Loberg, C., Kravets, H., Beheshti, M., von Mallek, D., Mottaghy, F. M., & Heinzel, A. (2019). Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor. EXCLI journal, 18273-276. https://doi.org/10.17179/excli2019-1220
Ataeinia, Bahar, et al. "Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor." EXCLI journal vol. 18 (2019): 273-276. doi: https://doi.org/10.17179/excli2019-1220
Ataeinia B, Loberg C, Kravets H, Beheshti M, von Mallek D, Mottaghy FM, Heinzel A. Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor. EXCLI J. 2019 May 21;18:273-276. doi: 10.17179/excli2019-1220. eCollection 2019. PMID: 31338000; PMCID: PMC6635723.
Copy Download .nbib Format: NLM
Brachydactyly mental retardation syndrome with growth hormone deficiency.

Endocrinology, diabetes & metabolism case reports

Arefzadeh A, Khalighinejad P, Ataeinia B, Parvar P.
PMID: 30087780
Endocrinol Diabetes Metab Case Rep. 2018 Jul 21;2018. doi: 10.1530/EDM-18-0068. eCollection 2018.

Deletion of chromosome 2q37 results in a rare congenital syndrome known as brachydactyly mental retardation (BDMR) syndrome; a syndrome which has phenotypes similar to Albright hereditary osteodystrophy (AHO) syndrome. In this report, we describe a patient with AHO due...

Cite
Arefzadeh A, Khalighinejad P, Ataeinia B, et al. Brachydactyly mental retardation syndrome with growth hormone deficiency. Endocrinol Diabetes Metab Case Rep. 2018;2018doi: 10.1530/EDM-18-0068.
Arefzadeh, A., Khalighinejad, P., Ataeinia, B., & Parvar, P. (2018). Brachydactyly mental retardation syndrome with growth hormone deficiency. Endocrinology, diabetes & metabolism case reports, 2018. https://doi.org/10.1530/EDM-18-0068
Arefzadeh, Alireza, et al. "Brachydactyly mental retardation syndrome with growth hormone deficiency." Endocrinology, diabetes & metabolism case reports vol. 2018 (2018). doi: https://doi.org/10.1530/EDM-18-0068
Arefzadeh A, Khalighinejad P, Ataeinia B, Parvar P. Brachydactyly mental retardation syndrome with growth hormone deficiency. Endocrinol Diabetes Metab Case Rep. 2018 Jul 21;2018. doi: 10.1530/EDM-18-0068. eCollection 2018. PMID: 30087780; PMCID: PMC6063990.
Copy Download .nbib Format: NLM
Non-invasive Detection of Immunotherapy-Induced Adverse Events.

Clinical cancer research : an official journal of the American Association for Cancer Research

Ferreira CA, Heidari P, Ataeinia B, Sinevici N, Sise ME, Colvin RB, Wehrenberg-Klee E, Mahmood U.
PMID: 34253581
Clin Cancer Res. 2021 Jul 12; doi: 10.1158/1078-0432.CCR-20-4641. Epub 2021 Jul 12.

PURPOSE: Cancer immunotherapy has markedly improved the prognosis of patients with a broad variety of malignancies. However, benefits are weighed against unique toxicities, with immune-related adverse events (irAE) that are frequent and potentially life-threatening. The diagnosis and management of...

Cite
Ferreira CA, Heidari P, Ataeinia B, et al. Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-20-4641.
Ferreira, C. A., Heidari, P., Ataeinia, B., Sinevici, N., Sise, M. E., Colvin, R. B., Wehrenberg-Klee, E., & Mahmood, U. (2021). Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-20-4641
Ferreira, Carolina A, et al. "Non-invasive Detection of Immunotherapy-Induced Adverse Events." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-20-4641
Ferreira CA, Heidari P, Ataeinia B, Sinevici N, Sise ME, Colvin RB, Wehrenberg-Klee E, Mahmood U. Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clin Cancer Res. 2021 Jul 12; doi: 10.1158/1078-0432.CCR-20-4641. Epub 2021 Jul 12. PMID: 34253581.
Copy Download .nbib Format: NLM
Non-invasive Detection of Immunotherapy-Induced Adverse Events.

Clinical cancer research : an official journal of the American Association for Cancer Research

Ferreira CA, Heidari P, Ataeinia B, Sinevici N, Sise ME, Colvin RB, Wehrenberg-Klee E, Mahmood U.
PMID: 34253581
Clin Cancer Res. 2021 Jul 12; doi: 10.1158/1078-0432.CCR-20-4641. Epub 2021 Jul 12.

PURPOSE: Cancer immunotherapy has markedly improved the prognosis of patients with a broad variety of malignancies. However, benefits are weighed against unique toxicities, with immune-related adverse events (irAE) that are frequent and potentially life-threatening. The diagnosis and management of...

Cite
Ferreira CA, Heidari P, Ataeinia B, et al. Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-20-4641.
Ferreira, C. A., Heidari, P., Ataeinia, B., Sinevici, N., Sise, M. E., Colvin, R. B., Wehrenberg-Klee, E., & Mahmood, U. (2021). Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-20-4641
Ferreira, Carolina A, et al. "Non-invasive Detection of Immunotherapy-Induced Adverse Events." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-20-4641
Ferreira CA, Heidari P, Ataeinia B, Sinevici N, Sise ME, Colvin RB, Wehrenberg-Klee E, Mahmood U. Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clin Cancer Res. 2021 Jul 12; doi: 10.1158/1078-0432.CCR-20-4641. Epub 2021 Jul 12. PMID: 34253581; PMCID: PMC8752648.
Copy Download .nbib Format: NLM
Trends of National and Subnational Incidence of Childhood Cancer Groups in Iran: 1990-2016.

Frontiers in oncology

Shabani M, Saeedi Moghaddam S, Ataeinia B, Rezaei N, Mohebi F, Mohajer B, Gohari K, Sheidaei A, Pishgar F, Yoosefi M, Kompani F, Farzadfar F.
PMID: 31993366
Front Oncol. 2020 Jan 14;9:1428. doi: 10.3389/fonc.2019.01428. eCollection 2019.

No abstract available.

Cite
Shabani M, Saeedi Moghaddam S, Ataeinia B, et al. Trends of National and Subnational Incidence of Childhood Cancer Groups in Iran: 1990-2016. Front Oncol. 2020;9:1428doi: 10.3389/fonc.2019.01428.
Shabani, M., Saeedi Moghaddam, S., Ataeinia, B., Rezaei, N., Mohebi, F., Mohajer, B., Gohari, K., Sheidaei, A., Pishgar, F., Yoosefi, M., Kompani, F., & Farzadfar, F. (2019). Trends of National and Subnational Incidence of Childhood Cancer Groups in Iran: 1990-2016. Frontiers in oncology, 91428. https://doi.org/10.3389/fonc.2019.01428
Shabani, Mahsima, et al. "Trends of National and Subnational Incidence of Childhood Cancer Groups in Iran: 1990-2016." Frontiers in oncology vol. 9 (2019): 1428. doi: https://doi.org/10.3389/fonc.2019.01428
Shabani M, Saeedi Moghaddam S, Ataeinia B, Rezaei N, Mohebi F, Mohajer B, Gohari K, Sheidaei A, Pishgar F, Yoosefi M, Kompani F, Farzadfar F. Trends of National and Subnational Incidence of Childhood Cancer Groups in Iran: 1990-2016. Front Oncol. 2020 Jan 14;9:1428. doi: 10.3389/fonc.2019.01428. eCollection 2019. PMID: 31993366; PMCID: PMC6970968.
Copy Download .nbib Format: NLM
Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.

Journal of clinical medicine

Manafi-Farid R, Masoumi F, Divband G, Saidi B, Ataeinia B, Hertel F, Schweighofer-Zwink G, Morgenroth A, Beheshti M.
PMID: 32806765
J Clin Med. 2020 Aug 12;9(8). doi: 10.3390/jcm9082622.

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through...

Cite
Manafi-Farid R, Masoumi F, Divband G, et al. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. J Clin Med. 2020;9(8)doi: 10.3390/jcm9082622.
Manafi-Farid, R., Masoumi, F., Divband, G., Saidi, B., Ataeinia, B., Hertel, F., Schweighofer-Zwink, G., Morgenroth, A., & Beheshti, M. (2020). Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. Journal of clinical medicine, 9(8), . https://doi.org/10.3390/jcm9082622
Manafi-Farid, Reyhaneh, et al. "Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain." Journal of clinical medicine vol. 9,8 (2020). doi: https://doi.org/10.3390/jcm9082622
Manafi-Farid R, Masoumi F, Divband G, Saidi B, Ataeinia B, Hertel F, Schweighofer-Zwink G, Morgenroth A, Beheshti M. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. J Clin Med. 2020 Aug 12;9(8). doi: 10.3390/jcm9082622. PMID: 32806765; PMCID: PMC7464823.
Copy Download .nbib Format: NLM
National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990.

Frontiers in oncology

Ataeinia B, Saeedi Moghaddam S, Shabani M, Gohari K, Sheidaei A, Rezaei N, Naderimagham S, Ghasemi E, Rouhifard Khalilabad M, Roshani S, Farzi Y, Farzadfar F.
PMID: 33842306
Front Oncol. 2021 Mar 25;11:561376. doi: 10.3389/fonc.2021.561376. eCollection 2021.

Breast cancer is the most common cancer among women, causing considerable burden and mortality. Demographic and lifestyle transitions in low and low-middle income countries have given rise to its increased incidence. The successful management of cancer relies on evidence-based...

Cite
Ataeinia B, Saeedi Moghaddam S, Shabani M, et al. National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990. Front Oncol. 2021;11:561376doi: 10.3389/fonc.2021.561376.
Ataeinia, B., Saeedi Moghaddam, S., Shabani, M., Gohari, K., Sheidaei, A., Rezaei, N., Naderimagham, S., Ghasemi, E., Rouhifard Khalilabad, M., Roshani, S., Farzi, Y., & Farzadfar, F. (2021). National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990. Frontiers in oncology, 11561376. https://doi.org/10.3389/fonc.2021.561376
Ataeinia, Bahar, et al. "National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990." Frontiers in oncology vol. 11 (2021): 561376. doi: https://doi.org/10.3389/fonc.2021.561376
Ataeinia B, Saeedi Moghaddam S, Shabani M, Gohari K, Sheidaei A, Rezaei N, Naderimagham S, Ghasemi E, Rouhifard Khalilabad M, Roshani S, Farzi Y, Farzadfar F. National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990. Front Oncol. 2021 Mar 25;11:561376. doi: 10.3389/fonc.2021.561376. eCollection 2021. PMID: 33842306; PMCID: PMC8027299.
Copy Download .nbib Format: NLM
Code of ethics for the national pharmaceutical system: Codifying and compilation.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Salari P, Namazi H, Abdollahi M, Khansari F, Nikfar S, Larijani B, Araminia B.
PMID: 24174954
J Res Med Sci. 2013 May;18(5):442-8.

Pharmacists as one of health-care providers face ethical issues in terms of pharmaceutical care, relationship with patients and cooperation with the health-care team. Other than pharmacy, there are pharmaceutical companies in various fields of manufacturing, importing or distributing that...

Cite
Salari P, Namazi H, Abdollahi M, et al. Code of ethics for the national pharmaceutical system: Codifying and compilation. J Res Med Sci. 2013;18(5):442-8
Salari, P., Namazi, H., Abdollahi, M., Khansari, F., Nikfar, S., Larijani, B., & Araminia, B. (2013). Code of ethics for the national pharmaceutical system: Codifying and compilation. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 18(5), 442-8.
Salari, Pooneh, et al. "Code of ethics for the national pharmaceutical system: Codifying and compilation." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 18,5 (2013): 442-8.
Salari P, Namazi H, Abdollahi M, Khansari F, Nikfar S, Larijani B, Araminia B. Code of ethics for the national pharmaceutical system: Codifying and compilation. J Res Med Sci. 2013 May;18(5):442-8. PMID: 24174954; PMCID: PMC3810583.
Copy Download .nbib Format: NLM
HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance.

Frontiers in oncology

Sinevici N, Ataeinia B, Zehnder V, Lin K, Grove L, Heidari P, Mahmood U.
PMID: 33330026
Front Oncol. 2020 Nov 20;10:554704. doi: 10.3389/fonc.2020.554704. eCollection 2020.

Triple Negative Breast Cancer (TNBC) is an aggressive form of Breast Cancer (BC). Numerous kinase inhibitors (KI) targeting different pathway nodes have shown limited benefit in the clinical setting. In this study, we aim to characterize the extent of...

Cite
Sinevici N, Ataeinia B, Zehnder V, et al. HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance. Front Oncol. 2020;10:554704doi: 10.3389/fonc.2020.554704.
Sinevici, N., Ataeinia, B., Zehnder, V., Lin, K., Grove, L., Heidari, P., & Mahmood, U. (2020). HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance. Frontiers in oncology, 10554704. https://doi.org/10.3389/fonc.2020.554704
Sinevici, Nicoleta, et al. "HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance." Frontiers in oncology vol. 10 (2020): 554704. doi: https://doi.org/10.3389/fonc.2020.554704
Sinevici N, Ataeinia B, Zehnder V, Lin K, Grove L, Heidari P, Mahmood U. HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance. Front Oncol. 2020 Nov 20;10:554704. doi: 10.3389/fonc.2020.554704. eCollection 2020. PMID: 33330026; PMCID: PMC7715030.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries